Effectiveness of COX2 Inhibitor Etoricoxib Treatment on Pain in Patients with Arthritis

Activity: Talk or presentation types › Oral presentation

Description

Evaluation effectiveness of COX2 inhibitor Etoricoxib, assessing pain intensity of patients diagnosed with arthritis. Observational prospective multicenter study was conducted in 62 family physician practices of Latvia in accordance with all requirements of ethics and good clinical practice; informed consent was obtained from all study participants. 801 patients were included: aged between 18-79; 473 (60% of all) women and 328 (40%) men. Inclusion criteria were patient compliance with the clinical indications for treatment with etoricoxib - symptomatic arthritis (osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis) according to the investigator’s consideration. All study participants received treatment with Etoricoxib once daily in dose 60 mg (67 patients), 90 mg (512 patients) or 120 mg (222 patients) for 8±4 weeks. Pain intensity was measured by VAS scale (from 0 to 100 mm) before and at the end of treatment period. Safety (cardiovascular, gastrointestinal) of treatment was assessed.. The mean of pain intensity in patients with symptomatic arthritis before treatment started was 50 ± 100 mm. Reduction of pain intensity is considered as clinically meaningful, if pain intensity in the end of treatment does not exceed 30 mm on VAS or if the baseline intensity is reduced for at least 50 %. In 607 patients (76% of all) at the end treatment pain intensity was reduced for at least 50 % from baseline. No significant adverse events were registered.. Treatment with Etoricoxib significantly reduces intensity of pain in majority of patients with arthritis.
Period29 Mar 2023
Event titleRSU International Research Conference 2023: Knowledge for Use in Practice
Event typeConference
OrganiserRīga Stradiņš University
LocationRiga, LatviaShow on map
Degree of RecognitionInternational

Related content